S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Globus Medical Stock Price, News & Analysis (NYSE:GMED)

$45.29
+0.83 (+1.87%)
(As of 12/7/2023 ET)
Compare
Today's Range
$44.02
$45.40
50-Day Range
$43.78
$55.14
52-Week Range
$43.38
$80.04
Volume
1.37 million shs
Average Volume
1.43 million shs
Market Capitalization
$6.24 billion
P/E Ratio
29.22
Dividend Yield
N/A
Price Target
$65.11

Globus Medical MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
43.8% Upside
$65.11 Price Target
Short Interest
Healthy
2.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
1.60mentions of Globus Medical in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.15%
From $2.31 to $2.66 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.52 out of 5 stars

Medical Sector

1st out of 960 stocks

Surgical & Medical Instruments Industry

1st out of 75 stocks


GMED stock logo

About Globus Medical Stock (NYSE:GMED)

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales presence, as well as its hip and knee products primarily through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

GMED Stock Price History

GMED Stock News Headlines

Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Globus Medical: Merger Overhang Lingering
Globus Medical (GMED) Q3 2023 Earnings Call Transcript
Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
When Should You Buy Globus Medical, Inc. (NYSE:GMED)?
Stifel Upgrades Globus Medical Inc - (GMED)
Globus Medical: Almost Having My Back
See More Headlines
Receive GMED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/20/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
37957720
Employees
2,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$65.11
High Stock Price Target
$86.00
Low Stock Price Target
$53.00
Potential Upside/Downside
+43.8%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
12 Analysts

Profitability

Net Income
$190.17 million
Pretax Margin
16.51%

Debt

Sales & Book Value

Annual Sales
$1.23 billion
Cash Flow
$2.80 per share
Book Value
$18.43 per share

Miscellaneous

Free Float
104,309,000
Market Cap
$6.24 billion
Optionable
Optionable
Beta
1.06
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report














GMED Stock Analysis - Frequently Asked Questions

Should I buy or sell Globus Medical stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMED, but not buy additional shares or sell existing shares.
View GMED analyst ratings
or view top-rated stocks.

What is Globus Medical's stock price target for 2024?

12 brokers have issued 12-month price targets for Globus Medical's stock. Their GMED share price targets range from $53.00 to $86.00. On average, they predict the company's stock price to reach $65.11 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price.
View analysts price targets for GMED
or view top-rated stocks among Wall Street analysts.

How have GMED shares performed in 2023?

Globus Medical's stock was trading at $74.27 at the beginning of 2023. Since then, GMED shares have decreased by 39.0% and is now trading at $45.29.
View the best growth stocks for 2023 here
.

Are investors shorting Globus Medical?

Globus Medical saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 3,680,000 shares, a decline of 7.8% from the October 31st total of 3,990,000 shares. Based on an average daily volume of 2,000,000 shares, the short-interest ratio is presently 1.8 days.
View Globus Medical's Short Interest
.

When is Globus Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our GMED earnings forecast
.

How were Globus Medical's earnings last quarter?

Globus Medical, Inc. (NYSE:GMED) issued its earnings results on Tuesday, November, 7th. The medical device company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.54 by $0.03. The medical device company earned $383.60 million during the quarter, compared to analyst estimates of $306.78 million. Globus Medical had a net margin of 12.88% and a trailing twelve-month return on equity of 9.79%. Globus Medical's revenue was up 51.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.50 EPS.

What guidance has Globus Medical issued on next quarter's earnings?

Globus Medical issued an update on its FY23 earnings guidance on Tuesday, November, 7th. The company provided earnings per share (EPS) guidance of $2.30 for the period, compared to the consensus EPS estimate of $2.30. The company issued revenue guidance of $1.55 billion, compared to the consensus revenue estimate of $1.13 billion.

What is David Demski's approval rating as Globus Medical's CEO?

47 employees have rated Globus Medical Chief Executive Officer David Demski on Glassdoor.com. David Demski has an approval rating of 61% among the company's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Globus Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Block (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA).

Who are Globus Medical's major shareholders?

Globus Medical's stock is owned by a number of institutional and retail investors. Top institutional investors include Nuance Investments LLC (3.60%), Wellington Management Group LLP (1.93%), Bank of New York Mellon Corp (2.40%), William Blair Investment Management LLC (2.31%), Hawk Ridge Capital Management LP (2.22%) and JPMorgan Chase & Co. (2.12%). Insiders that own company stock include Dan Lemaitre, Daniel T Scavilla, Daniel T Scavilla, David D Davidar, David M Demski, James R Tobin, James R Tobin, Keith W Pfeil, Keith W Pfeil and Kelly Huller.
View institutional ownership trends
.

How do I buy shares of Globus Medical?

Shares of GMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:GMED) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -